Supplementary Table S2 from Preclinical Evaluation of the Efficacy of the Cyclin-Dependent Kinase Inhibitor Ribociclib in Combination with Letrozole against Patient-Derived Glioblastoma Cells

Sidharth N. Gadgil; Aniruddha Sunil Karve; Gary A. Gudelsky; Bhavesh Babulal Gabani; Shravani Parag Kulkarni; Timothy N. Phoenix; Mario Medvedovic; David R. Plas; Trisha Michel Wise-Draper; Soma Sengupta; Biplab Dasgupta; Lalanthica Yogendran; Pankaj B. Desai

doi:10.1158/1535-7163.30985934

Supplementary Table S2 from Preclinical Evaluation of the Efficacy of the Cyclin-Dependent Kinase Inhibitor Ribociclib in Combination with Letrozole against Patient-Derived Glioblastoma Cells

2026 Open access

Read full text

Authors: Sidharth N. Gadgil, Aniruddha Sunil Karve, Gary A. Gudelsky, Bhavesh Babulal Gabani, Shravani Parag Kulkarni, Timothy N. Phoenix, Mario Medvedovic, David R. Plas, Trisha Michel Wise-Draper, Soma Sengupta, Biplab Dasgupta, Lalanthica Yogendran

+1 more

Pankaj B. Desai

DOI: 10.1158/1535-7163.30985934

Cited by: 0

Abstract

IC50 values for LTZ, ribociclib and combination of ribociclib with non-cytotoxic concentrations of LTZ against patient-derived GBM lines and EC50 values for neurosphere growth inhibition.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

Publication details

Publication date: 2 January 2026